Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylphenidate in disorders of consciousness
NCT03814356Phase 1Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Aug 2020
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of methylphenidate in disorders of consciousness (DoC), sponsored by Massachusetts General Hospital. Primary endpoint: Number of Participants With Adverse Events at Each Dose at 4 days. Started Aug 2020; status: active, not recruiting.
02
Drugs
methylphenidate
03
Conditions
disorders of consciousness (DoC)
Beyond the preview
Go deeper on NCT03814356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03814356.